Publications Office of the EU
SUPPLY OF EXCLUSIVE MEDICINAL PRODUCTS: TRASTUZUMAB 600MG. - EU tenders
DisplayCustomHeader
Procurement Detail Actions Portlet
OP Portal - Procurement - Details

This page contains content generated automatically to improve findability and accessibility

- indicates text translated automatically in your browsing language

SUPPLY OF EXCLUSIVE MEDICINAL PRODUCTS: TRASTUZUMAB 600MG.

  • Awarded
    12/09/2024
  • Today
    11/06/2026
Status
Awarded
Type of contract
Supplies
Subject for Renewal
No
Buyer
Hospital Universitario de la Princesa
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: ES300 Madrid
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
385,203.00 EUR
Tender reference number
P.N.S.P. 3/2024 HUP
Description

SUPPLY OF EXCLUSIVE MEDICINAL PRODUCTS: TRASTUZUMAB 600MG.

Submission Method
Not available
Tenders may be submitted
Not available
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
Not available
Place of performance
Award method
Criterion:
Type: price
Description: El precio es el único criterio de adjudicación
Weight (percentage, exact):
Estimated value
Not available
Final contracted value
385,203.00 EUR
Award of contract
Official name: ROCHE FARMA, S.A.
Postal address:
Town: Madrid
Postal code: 28042
Country:
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.